drugset / Trial / NCT07691073

Embryo QUAlity in Ovarian Stimulation With hMG.

NCT07691073

Phase 4 Not yet recruiting 240 enrolled Fundacion Dexeus Ferring Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.

Timeline

Start
2026-09
Primary completion
2029-02
Completion
2029-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Follitropin delta Protein / enzyme biologic 5 ug
Comparator Follitropin delta Protein / enzyme biologic 10 ug
Subject hMG Unknown 150 iu
Comparator hMG Unknown 150 iu
Subject hMG Unknown 225 iu
Comparator hMG Unknown 225 iu

Indications